The economic implications of glaucoma: A literature review

PharmacoEconomics

Volumn 25, Issue 4, 2007, Pages 287-308

  Schmier, Jordana K ^a   Halpern, Michael T ^a   Jones, Mechelle L ^a  

^a EXPONENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; ECONOMIC ASPECT; GLAUCOMA; HEALTH CARE COST; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

DRUG THERAPY; GLAUCOMA; HUMANS; META-ANALYSIS; SURGERY;

EID: 34247182137     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725040-00003     Document Type: Review

References (77)

1. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004 Apr; 122 (4): 532-8
2. American Academy of Ophthalmology. Preferred practice pattern: primary open-angle glaucoma. Limited revision. San Francisco (CA): American Academy of Ophthalmology, 2003
3. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA 1991 Jul 17; 266 (3): 369-74
4. Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001 Dec; 119 (12): 1819-26
5. Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004 Aug; 111 (8): 1439-48
6. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology 1992 Oct; 99 (10): 1499-504
7. Duggal P, Klein AP, Lee KE, et al. A genetic contribution to intraocular pressure: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 2005 Feb; 46 (2): 555-60
8. American Academy of Ophthalmology. Preferred practice pattern: primary open-angle glaucoma suspect. San Francisco (CA): American Academy of Ophthalmology, 2005
9. American Academy of Ophthalmology. Preferred practice pattern: primary angle closure glaucoma. Limited revision. San Francisco (CA): American Academy of Ophthalmology, 2005
10. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998 Oct; 126 (4): 498-505
11. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001 Nov; 108 (11): 1943-53
12. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration: the AGIS Investigators. Am J Ophthalmol 2000 Oct; 130 (4): 429-40
13. Baltussen RM, Sylla M, Frick KD, et al. Cost-effectiveness of trachoma control in seven world regions. Ophthalmic Epidemiol 2005 Apr; 12 (2): 91-101
14. Schmier JK, Halpern MT, Covert DW, et al. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration (AMD). Retina 2006; 26 (9): 1056-62
15. Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. Pharmacoeconomics 2006; 24 (4): 319-34
16. Sharma S, Hollands H, Brown GC, et al. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 2001 Jun; 12 (3): 230-4
17. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000 Feb 16; 283 (7): 889-96
18. Whited JD, Datta SK, Aiello LM, et al. A modeled economic analysis of a digital teleophthalmology system as used by three federal healthcare agencies for detecting proliferative diabetic retinopathy. Telemed J E Health 2005 Dec; 11 (6): 641-51
19. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006; 124 (1): 12-9
20. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004 Aug; 13 (4): 283-90
21. Calissendorff BM. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand 2001 Jun; 79 (3): 286-8
22. Ellwein LB, Urato CJ. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 2002 Jun; 120 (6): 804-11
23. Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma 2003 Dec; 12 (6): 456-62
24. Lindblom B, Nordmann JP, Sellem E, et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 2005; 82 (1): 73-83
25. Oostenbrink JB, Rutten-van Molken MP, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 1999; 98 (3): 285-99
26. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001 Jun; 10 (3): 184-91
27. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005 Oct; 89 (10): 1245-9
28. Vicente C, Walker J, Buys Y, et al. Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada. Curr Med Res Opin 2004 Aug; 20 (8): 1245-51
29. Wang JC, Chew PT. What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model. Clin Experiment Ophthalmol 2004 Dec; 32 (6): 578-83
30. Abelson MB, Netland PA, Chapin MJ. Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model. Adv Ther 2001 Nov-Dec; 18 (6): 282-97
31. Ainsworth JR, Jay JL. Cost analysis of early trabeculectomy versus conventional management in primary open angle glaucoma. Eye 1991; 5 (Pt 3): 322-8
32. Bernard LM, Althin R, Dhawan R, et al. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 2003 Jul; 13 Suppl. 4: S30-43
33. Christensen TL, Poulsen PB, Holmstrom S, et al. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy. Curr Med Res Opin 2005 Nov; 21 (11): 1837-44
34. Coast J, Spencer IC, Smith L, et al. Comparing costs of monitoring glaucoma patients: hospital ophthalmologists versus community optometrists. J Health Serv Res Policy 1997 Jan; 2 (1): 19-25
35. Day DG, Schacknow PN, Sharpe ED, et al. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2004 Oct; 20 (5): 383-92
36. Halpern MT, Covert DW, Robin AL. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc 2002; 100: 109-17-109; discussion 117-8
37. Kobelt G, Jonsson L. Modeling cost of treatment with new topical treatments for glaucoma: results from France and the United Kingdom. Int J Technol Assess Health Care 1999 Winter; 15 (1): 207-19
38. Kobelt G, Jonsson L, Gerdtham U, et al. Direct costs of glaucoma management following initiation of medical therapy: a simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998 Nov; 236 (11): 811-21
39. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998 Apr; 7 (2): 95-104
40. Marchetti A, Magar R, An P, et al. Clinical and economic impact of new trends in glaucoma treatment. MedGenMed 2001 Jul 26; 3 (4): 6
41. Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 2006 Jan; 141 (1 Suppl.): 15-21
42. Rocchi A, Tingey D. Economic evaluation of dorzolamide vs. nonpilocarpine for primary open-angle glaucoma. Can J Ophthalmol 1997 Oct; 32 (6): 414-8
43. Rouland JF, Le Pen C. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol 2003 Jul; 13 Suppl. 4: S5-20
44. Rouland JF, Le Pen C, Benhaddi H, et al. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 2 years. Eur J Ophthalmol 2005 Sep-Oct; 15 (5): 562-80
45. Stewart WC, Leech J, Sharpe ED, et al. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension. Am J Manag Care 2002 Aug; 8 (10 Suppl.): S240-8
46. Tuil E, Hommer AB, Poulsen PB, et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients: a European perspective. Int J Clin Pract 2005 Sep; 59 (9): 1011-6
47. Walt JG, Lee JT. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004 Mar; 49 Suppl. 1: S36-44
48. Calissendorff BM. Consumption of glaucoma medication. Acta Ophthalmol Scand 2001 Feb; 79 (1): 2-5
49. De Natale R, Draghi E, Dorigo MT. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications. Acta Ophthalmol Scand 2004 Aug; 82 (4): 393-6
50. Doyle JW, Smith MF, Tierney JW Jr. Glaucoma medical treatment: 2002. Does yearly cost now equal the year? Optom Vis Sci 2002 Aug; 79 (8): 489-92
51. Fiscella RG, Geller JL, Gryz LL, et al. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 1999 Oct; 128 (4): 426-33
52. Fiscella RG, Green A, Patuszynski DH, et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003 Jul; 136 (1): 18-25
53. Gelvin JB, Goen TM. Dosage cost analysis in glaucoma management. J Am Optom Assoc 1989 Oct; 60 (10): 768-70
54. Ikeda H, Tsukamoto H, Sawa A, et al. Comparison of annual cost between brand and generic ocular beta-adrenergic blockers. Yakugaku Zasshi 2005 May; 125 (5): 463-7
55. Kooner KS, Zimmerman TJ. The cost of antiglaucoma medications. Ann Ophthalmol 1987 Sep; 19 (9): 327-8
56. Mick AB, Gonzalez S, Dunbar MT, et al. A cost analysis of the prostaglandin analogs. Optometry 2002 Oct; 73 (10): 614-9
57. Stewart WC, Sine C, Cate E, et al. Daily cost of beta-adrenergic blocker therapy. Arch Ophthalmol. 1997 Jul; 115 (7): 853-6
58. Vold SD, Wiggins DA, Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma 2000 Apr; 9 (2): 150-3
59. Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 2002 Aug; 11 (4): 354-8
60. Jampel HD, Schwartz GF, Robin AL, et al. Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol 2003 Apr; 121 (4): 540-6
61. Jampel HD, Parekh P, Johnson E, et al. Preferences for eye drop characteristics among glaucoma specialists: a willingness-topay analysis. J Glaucoma 2005 Apr; 14 (2): 151-6
62. Lafuma A, Brezin A, Lopatriello S, et al. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics 2006; 24 (2): 193-205
63. Meads C, Hyde C. How much is the cost of visual impairment. Pharmacoeconomics 2006; 24 (2): 207-9
64. Spaeth G, Walt J, Keener J. Evaluation of quality of life for patients with glaucoma. Am J Ophthalmol 2006 Jan; 141 (1 Suppl.): 3-14
65. Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging 2005; 22 (4): 315-21
66. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005 Sep-Oct; 8 (5): 521-33
67. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies. Value Health 2003 Jan-Feb; 6 (1): 9-17
68. Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998 Jul-Aug; 1 (2): 131-47
69. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 Mar 25; 332 (7543): 699-703
70. Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost- effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother 2003 Oct; 4 (10): 1775-88
71. Boivin JF, McGregor M, Archer C. Cost effectiveness of screening for primary open angle glaucoma. J Med Screen 1996; 3 (3): 154-63
72. Eddy DM, Sanders LE, Eddy JF. The value of screening for glaucoma with tonometry. Surv Ophthalmol 1983 Nov-Dec; 28 (3): 194-205
73. Sheldrick JH, Sharp AJ. Glaucoma screening clinic in general practice: prevalence of occult disease, and resource implications. Br J Gen Pract 1994 Dec; 44 (389): 561-5
74. Gottlieb LK, Schwartz B, Pauker SG. Glaucoma screening: a cost-effectiveness analysis. Surv Ophthalmol 1983 Nov-Dec; 28 (3): 206-26
75. Jones SJ, Vernon SA, Cater L, et al. Costing a community based screening programme for the detection of glaucoma. Eye 1990; 4 (Pt 1): 98-102
76. Harasymowycz P, Kamdeu Fansi A, Papamatheakis D. Screening for primary open-angle glaucoma in the developed world: are we there yet? Can J Ophthalmol 2005 Aug; 40 (4): 477-86
77. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2002 Dec; 11 (6): 531-9